On 10 June 2016 Innate Immunotherapeutics Limited (ASX:IIL) (“Innate”) announced that it was undertaking a rights issue (“Rights Issue”) to raise up to A$3,025,000 and that it had completed a private placement ("Placement") of 10,009,032 ordinary shares to sophisticated U.S. investors to raise approximately A$2.4 million.
The Rights Issue was structured on the basis of one new share for every nine existing shares (1 for 9) held at an issue price of A$0.25 (or NZ$0.27) being approximately equal to the Placement price and representing a 12% discount to the volume weighted average market price for Innate shares, calculated over 10 days prior to 9 June 2016. Participating shareholders were also able to apply for Additional New Shares in excess of their 1 for 9 entitlement.
For further information please download PDF attached:
Download this document
